Background: Identifying cancer risks associated with medicinal agents plays an important role in cancer control and prevention. Case reports of cancers associated with pharmacotherapy have been escalating in the Food and Drug Administration Adverse Event Reporting System (FAERS). The objective of this study is to assess the risk of pancreatic cancer associated with anti-diabetic drugs of dipeptidyl peptidase 4 (DPP 4) inhibitors with or without combination of metformin.
Methods:Using the FAERS public database, the adverse event reports (ADRs) associated with widely used DPP 4 inhibitors with or without combination of metformin were generated and evaluated. Standardized pharmacovigilance tools were applied to detect the signal for cancer risks by calculating the proportional reporting ratio (PRR) and the reporting odds ratio (ROR).
Results
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.